Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $2.17 Analyst target: $19.00 Upside: 775.58%
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs in the areas of oncology and infectious diseases. The company is headquartered in Seattle, Washington.
See the full interactive analysis & chart →Informational only — not investment advice.